Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTRACISE: Transdermal Estradiol and Exercise in Prostate Cancer
NCT06271551Phase 2Not yet recruiting
- Sponsor
- Central Finland Hospital District
- Start
- Mar 2024
- Primary completion
- Dec 2028
- Modality
- Hormone, Biologic
01
Overview
Phase 2, randomised, open-label trial of estradiol in prostate cancer (PCa) (2 arms), sponsored by Central Finland Hospital District. Primary endpoint: Expanded Prostate Cancer Index Composite Sexual Function Domain Score at 12 months. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
estradiol
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06271551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06271551.